Consistency Among CDRH Review Divisions Improves, But Industry Wants More
This article was originally published in The Gray Sheet
Executive Summary
A new report from the California Healthcare Institute shows a positive convergence of performance among FDA’s device review divisions, but the biomedical industry group thinks more policy reforms that build on models from the best performing CDRH divisions and branches might be warranted.